PARENTERAL SOLUTIONS CONTAINING METOLAZONE
Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D 5 W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.
1 . A quinazoline solution suitable for parenteral administration comprising an anti-hypertensive/diuretic compound of the formula
Where the X is halogen:
R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen and alkyl having from 1 to 6 carbon atoms and R 5 is hydrogen or alkyl group having 1 to 6 carbon atoms, dissolved in 1% DMAC having a pH of from about 6.8 to 8.
2 . A solution suitable for parenteral administration according to claim 1 wherein the quinazoline sulfonamide is metolazone dissolved in mixtures containing N,N-dimethylacetamide, PEG 300, 400, 600, polypropylene glycol, D 5 W and other suitable glycols at pH ranging from 6.8 to 8 with a concentration of metolazone ranging from 1 to 15 mg/ml.
3 . A solution of metolazone for the treatment of a patient suffering from hypertension, congestive heart failure or other edematous states which comprises the intravenous administration of an effective amount of a solution according to claims 1 and 2 .
4 . Solution of metolazone for treating edematous states due to cardiac, renal or hepatic dysfunction.
5 . A solution of metolazone for the treatment of edematous states not responsive to loop diuretics such as furosemide, alone wherein the combination of a loop diuretic in conjunction with metolazone causes an increase diuresis more than with either drug given alone.